QRG Capital Management Inc. Sells 13,671 Shares of United Therapeutics Corporation $UTHR

QRG Capital Management Inc. lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 76.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,099 shares of the biotechnology company’s stock after selling 13,671 shares during the quarter. QRG Capital Management Inc.’s holdings in United Therapeutics were worth $1,718,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in UTHR. AQR Capital Management LLC grew its position in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after acquiring an additional 364,713 shares during the period. Invesco Ltd. increased its holdings in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares in the last quarter. Assetmark Inc. boosted its position in United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares during the last quarter. Norges Bank bought a new position in United Therapeutics in the second quarter valued at about $136,453,000. Finally, Amundi grew its position in shares of United Therapeutics by 3.6% during the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock worth $107,113,000 after buying an additional 12,633 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the transaction, the director directly owned 4,190 shares in the company, valued at $2,136,900. This trade represents a 19.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 571,314 shares of company stock valued at $269,609,063. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $464.93 on Tuesday. The firm has a market cap of $20.02 billion, a PE ratio of 17.62, a P/E/G ratio of 2.42 and a beta of 0.84. The business’s 50 day simple moving average is $487.07 and its 200 day simple moving average is $410.84. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period last year, the business earned $6.39 EPS. The business’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. HC Wainwright upped their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company boosted their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. UBS Group increased their target price on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a report on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.